Veradermics, Incorporated (MANE) Stock
Veradermics stock price chart
MANE stock quote & key statistics
Veradermics annual financials
Income statement →| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $0 | -$70.0M | -$104.54 |
| FY2024 | $0 | -$26.5M | — |
| FY2023 | $0 | -$16.5M | — |
Fiscal year ending December 31. Source: company filings via EODHD.
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum.
Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
Veradermics stock FAQ
What is the Veradermics stock ticker symbol?
Veradermics, Incorporated trades on the NYSE under the ticker symbol MANE.
What sector and industry is Veradermics in?
Veradermics, Incorporated is classified in the Healthcare sector, Biotechnology industry.
How many employees does Veradermics have?
Veradermics, Incorporated has about 37 full-time employees.
What were Veradermics's revenue and earnings last fiscal year?
Veradermics reported revenue of $0 and net income of -$70.0M in fiscal 2025, with earnings per share of -$104.54.
Is Veradermics in the Russell 2000?
Yes. Veradermics, Incorporated (MANE) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.
When did Veradermics go public?
Veradermics stock began trading on February 4, 2026.
Russell 2000 Biotechnology stocks
All Russell 2000 →- CGONCG Oncology
- COGTCogent Biosciences
- CRSPCRISPR Therapeutics
- CYTKCytokinetics
- DFTXDefinium Therapeutics
- DNTHDianthus Therapeutics
- IBRXImmunityBio
- IOVAIovance Biotherapeutics
- KODKodiak Sciences
- KRYSKrystal Biotech
- KYMRKymera Therapeutics
- LGNDLigand Pharmaceuticals
- MIRMMirum Pharmaceuticals
- ORKAOruka Therapeutics
- PCVXVaxcyte
- PRAXPraxis Precision Medicines
- PTCTPTC Therapeutics
- PTGXProtagonist Therapeutics
- RYTMRhythm Pharmaceuticals
- SRRKScholar Rock
- SYRESpyre Therapeutics
- TGTXTG Therapeutics
- TVTXTravere Therapeutics
- TWSTTwist Bioscience